Answers are grounded in this paper and cite their sources.
Cisplatin analogues, cis-dichloro(ethylenediamine-N,N′-di-3-propanoic acid)platinum(II) (1) and cis-iodo(ethylenediamine-N,N′-di-3-propanoic acid)platinum(II) (2), as well as trans-dichloro-(ethylenediamine-N,N′-di-3-propanoato)platinum(IV) (3), trans-dibromo(ethylenediamine -N,N′-di-3-propanoato)platinum(IV) (4), trans-dichloro(propylenediamine-N,N′-diacetato)-platinum(IV) (5) and trans-dibromo(propylenediamine-N,N′-diacetato)platinum(IV) (6), -([Pt(H2eddp)Cl2], [Pt(Heddp)I], trans-[Pt(eddp)Cl2], trans-[Pt(eddp)Br2], trans-[Pt(pdda)Cl2] and trans-[Pt(pdda)Br2], respectively) were used to assess antitumor selectivity against human adenocarcinoma HeLa cells. The results show that different oxidation states of platinum, different halide ligands, chelating aminocarboxylato and diamine backbones have similar effects with edda-type ligands and activity is lower than for cisplatin.
No takes yet. Share an insight, caveat, or question.
Kaluđerović et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: